Valeritas (VLRX) Sees Large Volume Increase
Valeritas Holdings Inc (NASDAQ:VLRX) shares saw unusually-strong trading volume on Thursday . Approximately 6,284 shares traded hands during mid-day trading, a decline of 97% from the previous session’s volume of 247,491 shares.The stock last traded at $1.42 and had previously closed at $1.29.
Several analysts have weighed in on VLRX shares. Oppenheimer set a $4.00 target price on Valeritas and gave the company a “buy” rating in a report on Tuesday, August 7th. started coverage on Valeritas in a report on Thursday, July 5th. They issued an “outperform” rating and a $3.50 target price on the stock. ValuEngine raised Valeritas from a “hold” rating to a “buy” rating in a report on Saturday, June 2nd. Finally, Citigroup assumed coverage on Valeritas in a report on Thursday, July 5th. They issued an “outperform” rating and a $3.50 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Valeritas presently has an average rating of “Buy” and a consensus price target of $3.67.
The company has a quick ratio of 3.42, a current ratio of 4.03 and a debt-to-equity ratio of 13.66. The stock has a market cap of $24.86 million, a PE ratio of -0.16 and a beta of 4.14.
Several large investors have recently modified their holdings of the company. C WorldWide Group Holding A S lifted its position in shares of Valeritas by 28.0% in the second quarter. C WorldWide Group Holding A S now owns 316,194 shares of the company’s stock valued at $424,000 after acquiring an additional 69,216 shares in the last quarter. Bainco International Investors purchased a new stake in shares of Valeritas in the second quarter valued at $228,000. Finally, Essex Investment Management Co. LLC purchased a new stake in shares of Valeritas in the second quarter valued at $448,000. Institutional investors and hedge funds own 7.38% of the company’s stock.
Valeritas Company Profile (NASDAQ:VLRX)
Valeritas Holdings, Inc, a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States and China. It offers V-Go, a wearable insulin delivery device for basal-bolus therapy. The company also develops h-Patch, a controlled delivery technology platform; Mini-Ject technology for needle-free injection systems; and Micro-Trans technology for microneedle design, fabrication, and drug delivery.
Further Reading: Do Tariffs Work?
Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.